Harvard Bioscience Adds to Neuroscience Products
The acquired product line includes probes, probe accessories, syringe pumps and related accessories, and instruments, such as fraction collectors. Microdialysis monitors the chemistry of living tissues’ extracellular space and is used for in vivo studies for drug delivery, drug metabolism, PK/PD, bioavailability, bioequivalence and pharmacological efficacy.
Holliston, MA 7/1/11—Harvard Bioscience has acquired the preclinical research business of CMA Microdialysis through a purchase of assets. Microdialysis is used for in vivo sampling and monitoring of organs and tissues. “The acquisition of CMA Microdialysis’ preclinical business provides Harvard with a leading technology to add to our line of specialized tools for biological research,” stated Harvard Bioscience CEO Chane Graziano. “The business unit will remain in Sweden under the leadership of Erik Düring.” The acquisition is expected to be immediately accretive to earnings. The purchase includes the CMA Microdialysis name.
